Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tisagenlecleucel - Novartis/University of Pennsylvania

Next Previous
Drug Profile

Tisagenlecleucel - Novartis/University of Pennsylvania

Alternative Names: Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Novartis; Anti-CD19-chimeric-antigen-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-chimeric-immune-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-CIR-retroviral-vector-transduced-autologous-T-cell-therapy-Novartis; CART-019; CART-19; CART-19 cells; CART-19-cells-Novartis; CART19-Novartis; CD19-targeted-chimeric-antigen-receptor-immunotherapy-Novartis; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL-019; Kimria; Kymriah; LG-740; tisagenlecleucel; tisagenlecleucel-T

Latest Information Update: 25 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor B-cell lymphoblastic leukaemia-lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Multiple myeloma
  • No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Breast cancer; Lymphoma; Mantle-cell lymphoma; Mesothelioma; Ovarian cancer; Pancreatic cancer
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse events data from the phase II CASSIOPEIA trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 03 Feb 2026 Novartis Pharmaceuticals completes the phase III BELINDA trial in Non-Hodgkin's lymphoma (Second-line therapy or greater, In adults, In the elderly) in USA, Australia, Austria, France, Germany, Hong Kong, Italy, Japan, Netherlands, Norway, Singapore, Spain, Switzerland, the UK, Belgium, Brazil, China and Taiwan (IV) (NCT03570892) (EudraCT2016-002966-29)
  • 28 May 2025 Novartis Pharmaceuticals completes a phase II ELARA trial in Follicular lymphoma (Second-line therapy or greater) in United Kingdom, Italy, Germany, Netherlands, Spain, France, Austria, Belgium, Norway, Japan, Australia and USA (IV, Infusion) (EudraCT2017-004385-94) (NCT03568461)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top